Apis Capital Advisors LLC Purchases New Shares in Dyadic International Inc. $DYAI

Apis Capital Advisors LLC purchased a new position in shares of Dyadic International Inc. (NASDAQ:DYAI) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,540,000 shares of the biotechnology company’s stock, valued at approximately $1,817,000. Apis Capital Advisors LLC owned 4.26% of Dyadic International at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the third quarter valued at about $190,000. Bank of America Corp DE increased its position in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. Marathon Capital Management purchased a new stake in Dyadic International during the 3rd quarter valued at approximately $41,000. Truist Financial Corp raised its stake in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 76,200 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its position in Dyadic International by 627.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 300,200 shares during the period. 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Trading Down 0.6%

Shares of DYAI stock opened at $0.76 on Friday. The business’s fifty day moving average price is $0.85 and its 200 day moving average price is $0.95. The firm has a market capitalization of $27.50 million, a PE ratio of -3.17 and a beta of 1.29. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85. Dyadic International Inc. has a 1-year low of $0.71 and a 1-year high of $1.55.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Dyadic International presently has a consensus rating of “Hold” and an average target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.